UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

~~December~~January 1612, ~~2023~~2024

Aridis Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38630		47-2641188
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

983 University Avenue, Bldg. B

Los Gatos, California 95032

(Address of principal executive offices, including ZIP code)

(408) 385-1742

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock		ARDS		OTC QB

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.0307. ~~Amendments~~Submission ~~to Articles~~ of ~~Incorporation~~Matters orto ~~Bylaws;~~a ~~Change~~Vote inof ~~Fiscal~~Security ~~Year.~~Holders

On ~~December~~January 1612, ~~2023~~2024, ~~the Board of Directors of~~ Aridis Pharmaceuticals, Inc. (the “Company”) ~~approved~~held anits ~~amendment~~Annual Meeting of ~~the~~Stockholders ~~Company’s Bylaws~~ (the “~~Bylaws~~Annual Meeting”). toA ~~change~~total ~~the~~of 15,313,250 shares of common stock, constituting a quorum, ~~for~~were ~~stockholder~~represented ~~meetings~~in toperson ~~equal~~or ~~one-third~~by ~~(33.33%)~~valid ofproxies at the ~~shares~~Annual ~~issued~~Meeting. ~~and outstanding~~The ~~and~~final ~~entitled~~results tofor ~~vote~~each onof the matters submitted to a vote of stockholders at the ~~meeting.~~Annual ~~The~~Meeting, ~~change~~as toset forth in the ~~quorum~~Definitive ~~requirement~~Proxy ~~for~~Statement, ~~stockholder~~filed ~~meetings~~with ~~was~~the ~~made to~~Securities ~~improve~~and ~~the~~Exchange ~~Company’s~~Commission ~~ability~~on toNovember ~~hold~~3, ~~stockholder~~2023 ~~meetings~~are ~~when~~as ~~called.~~follows:

~~The~~Proposal ~~foregoing~~1. ~~description~~Susan ofWindham-Bannister, ~~the~~Ph.D. ~~amendment~~was iselected ~~qualified~~as ina ~~its~~Class ~~entirety~~II bydirector ~~reference~~ to serve until the ~~full~~2026 ~~text~~Annual Meeting of ~~the~~Stockholders ~~Amendment~~or tountil her ~~the~~successor ~~Company’s Bylaws~~has been duly elected and qualified, ~~which~~or isuntil ~~filed~~her asearlier ~~Exhibit~~resignation, ~~3.1~~removal toor ~~this~~death. ~~Current~~The ~~Report~~result onof ~~Form~~the ~~8-K~~vote ~~and~~to iselect Susan ~~incorporated~~Windham-Bannister bywas ~~reference~~as ~~herein.~~follows:

Item 9.01. Financial Statements and Exhibits

Directors		For		Against		Abstain		Broker Non Vote
Susan Windham-Bannister		13,643,878		0		396,561		1,272,811

~~(d)~~Proposal ~~Exhibits~~2. The appointment of Grassi & Co., CPAs, P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2023 was ratified and approved by the stockholders by the votes set forth in the table below:

3.1	Amendment to Bylaws of Aridis Pharmaceuticals, Inc.
For		Against	Abstain	Broker Non Vote
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)
14,978,646		167,331	167,273	0

Proposal 3. The non-binding advisory vote to approve the compensation of our principal executive officer, principal financial officer and each of our three other most highly compensated executive officers as of December 31, 2022 (collectively, the “Named Executive Officers”) was approved by the stockholders by the votes set forth in the table below:

For		Against		Abstain		Broker Non Vote
11,359,540		1,361,875		1,319,023		1,272,812

Proposal 4. The 2023 Omnibus Equity Incentive Plan was approved by the stockholders by the votes set forth in the table below:

For		Against		Abstain		Broker Non Vote
11,530,834		1,369,001		1,140,604		1,272,811

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 18, 2023	ARIDIS PHARMACEUTICALS, INC.
Date: January 16, 2024	ARIDIS PHARMACEUTICALS, INC.
	/s/ Vu Truong
	Vu Truong
	Chief Executive Officer

-3-

Filing Compare · Aridis Pharmaceuticals, Inc.